Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product l… For the full story, visit the source.
Business
Sun Pharma guides for slower FY27 growth amid regulatory, macro challenges
Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product l…
By Jessica Jani· Livemint· 6 days ago· 2 min read
This summary is sourced from Livemint. Read the full article at:Livemint